MedTrace Logo

Oral Postbiotics in Patients With Macular Atrophy

NCT05391074 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-06-24

No results posted yet for this study

Summary

A pilot study to evaluate the safety and efficacy of oral therapy with Postbiotics in patients with geographic atrophy secondary to age-related macular degeneration, myopia, or angioid streaks.

Conditions

Interventions

DIETARY_SUPPLEMENT

postbiotics (IGENH35.3A)

postbiotics to induce microbiota epigenetic factors

DIETARY_SUPPLEMENT

vitamins (AREDS formulation and recommended daily dose)

vitamins (AREDS to prevent AMD progression

Sponsors & Collaborators

  • Igen BioLab SLU

    collaborator INDUSTRY

  • Institut de la Macula y la Retina

    lead OTHER

Principal Investigators

  • Jordi Monés, MD, PhD · Institut de la Màcula

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2023-12-01
Completion
2024-06-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05391074 on ClinicalTrials.gov